Département des Laboratoires Cliniques, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Int J Lab Hematol. 2021 Jun;43(3):450-457. doi: 10.1111/ijlh.13388. Epub 2020 Nov 13.
Evaluation of an individual's thrombin-generating capacity enables a global assessment of the coagulation cascade and is therefore thought to better reflect the clotting function of blood. However, the lack of standardization still hampers the use in routine clinical practice.
Nineteen healthy subjects were sampled once a week for 5 consecutive weeks. Thrombin generation assay (TGA) was performed in duplicate by calibrated automated thrombogram (CAT) on platelet poor plasma with and without thrombomodulin. After exclusion of outliers, a nested analysis of variance (ANOVA) was performed to evaluate the biological variability (BV) results. Analytical variation (CV ), within-individual variation (CV ), between-individual variation (CV ), index of individuality (II), and reference change value (RCV) were calculated.
All parameters taken together, the CV CV , and CV without TM, ranged from 2.8% to 6.5%, from 4.1% to 13.3% and from 10.4% to 28.4%, respectively. For TG with TM, CV and CV were higher and ranged from 5.0% to 18.1% and from 14.9% to 35.3%, respectively. For endogenous thrombin potential (ETP), a CV of 4.1% and CV of 10.4% were obtained without addition of thrombomodulin (TM). With addition of TM, both CV and CV were higher: 14.0% and 34.8%, respectively. The II was low and the RCV ranged from 17.2% to 50.4%.
CAT parameters are highly individualized and population-based reference values could be called into question. The assessment of BV and RCV for thrombin generation assays could optimize interpretation of serial patient results and guide setting of analytical specification goals.
评估个体的凝血酶生成能力可以全面评估凝血级联反应,因此被认为能更好地反映血液的凝血功能。然而,缺乏标准化仍然阻碍了其在常规临床实践中的应用。
19 名健康受试者连续 5 周每周采集一次样本。采用校准的自动血栓图(CAT)在血小板缺乏的血浆中重复进行两次凝血酶生成试验(TGA),并分别加入和不加入血栓调节蛋白(TM)。剔除离群值后,采用嵌套方差分析(ANOVA)评估生物学变异(BV)结果。计算分析变异(CV)、个体内变异(CV)、个体间变异(CV)、个体指数(II)和参考变化值(RCV)。
所有参数综合来看,无 TM 时的 CV CV 和 CV 分别为 2.8%6.5%、4.1%13.3%和 10.4%28.4%。有 TM 时的 CV 和 CV 较高,分别为 5.0%18.1%和 14.9%35.3%。对于内源性凝血酶潜能(ETP),不添加血栓调节蛋白(TM)时,CV 为 4.1%,CV 为 10.4%。添加 TM 后,CV 和 CV 均升高:分别为 14.0%和 34.8%。II 较低,RCV 范围为 17.2%50.4%。
CAT 参数具有高度个体性,基于人群的参考值可能值得质疑。评估凝血酶生成试验的 BV 和 RCV 可以优化对连续患者结果的解释,并指导分析规范目标的设定。